Table 8.

Therapeutic effects of OPC-20011, ABPC, and VCM in an experimental murine model of respiratory tract infection caused by S. pneumoniae T0005a

CompoundcDose (mg/kg)Log viable bacilli in lungsb (± SD)
SingleThree times
Control06.42 ± 0.827.21 ± 0.5
OPC-200112.54.0 ± 1.5* <1**
53.08 ± 1.18* <1**
101.73 ± 0.89** <1**
200.84 ± 1.03** <1**
ABPC2.56.02 ± 1.086.23 ± 1.51
55.55 ± 1.523.67 ± 0.73**
103.76 ± 2.282.09 ± 0.96**
202.98 ± 1.29* 1.73 ± 0.95**
VCM55.09 ± 1.194.11 ± 2.1*
105.43 ± 1.81<1**
204.40 ± 1.2<1**
403.72 ± 2.09<1**
  • a Challenge dose was 2.75 × 103 CFU/mouse.

  • b Viable bacilli in lungs were counted at 24 h after final treatment. Single, single treatment at 24 h after infection; three times, treatments at 24, 40, and 48 h after infection. The difference between the control and each treated group was determined by using a two-tailed Dunnett’s test (*, P < 0.05; **, P < 0.01).

  • c MICs of OPC-20011, ABPC, and VCM againstS. pneumoniae T0005 were 0.003, 0.2, and 0.39 μg/ml, respectively.